NCT04795947

Brief Summary

According to the prevalence survey of thyroid diseases in ten cities in China in 2010, TSH\>4.2 mIU /L was the diagnostic cut-off point, and the prevalence of hypothyroidism was 17.8%, including 1.1% clinical hypothyroidism.The annual incidence of hypothyroidism in China is 2.9‰, and primary hypothyroidism is the most common.Typical patients have chilliness, fatigue, swelling of hands and feet, lethargy, memory loss, hypoperspiration, joint pain, weight gain, constipation, menstrual disorder or menorrhagia, infertility, which affects the physiological and psychological functions of patients and reduces the quality of life of patients.The treatment goal of primary clinical hypothyroidism is that the symptoms and signs of hypothyroidism disappear, and TSH, TT4 and FT4 values remain in the normal range.Levothyroxine (L-T4) is the main alternative therapy for this disease.Thyroid disease patients quality of life questionnaire (Thyroid - specific Patient Reported Outcome, ThyPRO) for the development of the Danish scholars such as WATT first can be applied to various comprehensive scale of benign Thyroid disease patients, applied in the Danish people has good reliability and validity, has been translated into ten languages application in many countries the crowd, WATT et al in 2015 developed the scale of the concise version (ThyPRO39).Studies have shown that in the treatment of patients with thyroid disease, even if thyroid function is within the normal range, there are still physiological or psychological impairments such as chills, fatigue, anxiety, depression, which reduces the quality of life of patients.Studies have shown that TSH level in patients with hypothyroidism is correlated with patients' quality of life. Even within the normal range, the higher TSH level is, the worse the patients' quality of life score is, and there is an independent correlation in fatigue and emotional susceptibility. This study except for other factors, such as merger disease with primary hypothyroidism patients quality of life assessment, observe the normal JiaJian patients, we use the current widely used thyroid disease patients to evaluate the quality of life questionnaire (ThyPRO - 39), observe thyroid hormone levels in patients with hypothyroidism and their quality of life scale and the relevance of the blood sugar, blood lipid metabolic indicators related to relevance.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
98

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2020

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 10, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 12, 2021

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2021

Completed
Last Updated

March 12, 2021

Status Verified

March 1, 2021

Enrollment Period

1 year

First QC Date

March 10, 2021

Last Update Submit

March 10, 2021

Conditions

Keywords

Hypothyroidism

Outcome Measures

Primary Outcomes (1)

  • Thyroid-specific Patient Reported Outcome(ThyPRO39)

    Correlation between thyroid function level and health-related quality of life (HRQOL) and metabolic indexes.

    1year

Secondary Outcomes (1)

  • the MOS 36-item Short Form Health Survey(SF36)

    baseline

Interventions

BehavioralBEHAVIORAL

There is no intervention in this study

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with hypothyroidism in Chaoyang Hospital outpatient department

You may qualify if:

  • Male or female aged ≥18, ≤75 years old;
  • clear diagnosis of primary hypothyroidism;
  • Use the same dose of levothyroxine for ≥3 months;
  • The levels of thyroid function (TSH, TT4, FT4, TT3, FT3) in hospital laboratory blood tests no more than 6 weeks before participation were within the normal range;

You may not qualify if:

  • regnancy or lactation women
  • affect blood sugar, blood lipid metabolism drugs
  • serious heart disease
  • thyroid malignant tumor
  • history of mental illness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BeijingCYH

Beijing, Beijing Municipality, 100020, China

Location

MeSH Terms

Conditions

Hypothyroidism

Condition Hierarchy (Ancestors)

Thyroid DiseasesEndocrine System Diseases

Study Officials

  • Guang Wang

    Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Endocrinology

Study Record Dates

First Submitted

March 10, 2021

First Posted

March 12, 2021

Study Start

November 1, 2020

Primary Completion

November 1, 2021

Study Completion

November 1, 2021

Last Updated

March 12, 2021

Record last verified: 2021-03

Locations